Ovarian Cancer Breakthrough
NHS Approves Elahere, First Ovarian Cancer Drug in 20 Years, Boosting Survival for Hundreds
The NHS has approved mirvetuximab soravtansine, branded Elahere, for women with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancers—the first new treatment for this group in more than 20 years. Clinicians and patient advocates called the decision a major milestone, noting that many women are diagnosed at an advanced stage and historically faced limited options once chemotherapy stopped working. The therapy is an antibody-drug conjugate designed to “home” in on FRα proteins on cancer cells and is given by intravenous drip every three weeks. Trial results cited across coverage found it delayed disease progression and improved survival by an average of about four extra months versus chemotherapy alone, with better tolerability than the aggressive regimens previously relied on. Some reports also highlight substantial tumor shrinkage for a sizable share of patients and an expectation that NHS uptake could benefit hundreds of women per year in England.
Key Points
NHS England said the new drug could benefit “up to 400 women a year in England,” calling it “the most significant breakthrough… in over two decades.” Prof Ruth Plummer, NHS England’s national clinical lead for cancer drugs, said the approval will offer “hundreds of women” precious extra time.
In the global trial reported by coverage, involving “eight NHS hospitals,” average survival increased from 12.8 months to 16.5 months—an improvement framed by clinicians as about a 30% survival gain.
Tumour shrinkage data were more specific than just “a sizable share”: more than one-third of patients (reported as 37%) saw tumours shrink by at least 30%, compared with 16% with chemotherapy alone.
A key part of the clinical argument focused on tolerability versus traditional chemotherapy. UCL consultant oncologist Dr Rowan Miller contrasted the new drug’s every-three-weeks schedule with typical chemotherapy requiring frequent hospital visits and being associated with “hair loss, nerve damage, nausea” and patients “feel quite unwell.”
One report highlighted the clinical desperation before the approval: ovarian cancer affects “7,700 women” in the UK each year and “around 60 per cent” die; and for many historically “the only option… has been palliative care” once chemotherapy stopped working.
Sentiment
Mostly PositivePublishers
12
Articles
44
Reach
56
